On August 14, 2026, the clinical trial registry updated the status of a study involving corticotropin to terminated. The trial, titled "Prevention of West Syndrome With Low-dose Adrenocorticotropin Hormone (ACTH)," was registered under identifier NCT01367964. The study phase is listed as not applicable. According to the registry record, the trial's current status is terminated as of the date reported.
No results, efficacy data, or safety findings are included in this update. The registry entry does not state the reason for termination. This brief reports only the status change as recorded in the clinical trial database, without further detail on outcomes or rationale.
Corticotropin, also known as ACTH, is an approved compound. This particular trial examined its use in a low-dose format for the prevention of West Syndrome, a condition affecting infants. The termination status means the study did not proceed to completion as originally planned, though the registry does not specify further circumstances.
Readers seeking more background on corticotropin, including its approved uses and general profile, can consult the compound overview for additional context.